Olaparib/Cediranib Misses Survival End Points in Relapsed Ovarian Cancer Trial - OncLive
Maintenance olaparib plus cediranib did not significantly improve PFS or OS vs olaparib alone in relapsed platinum-sensitive ovarian cancer patients, according to the phase 3 ICON9 study. Median PFS was 11.0 months vs 13.9 months, and median OS was 37.8 months vs 37.2 months, with no statistical significance. Safety profiles were consistent with expected toxicities.
Related Clinical Trials
Reference News
Olaparib/Cediranib Misses Survival End Points in Relapsed Ovarian Cancer Trial - OncLive
Maintenance olaparib plus cediranib did not significantly improve PFS or OS vs olaparib alone in relapsed platinum-sensitive ovarian cancer patients, according to the phase 3 ICON9 study. Median PFS was 11.0 months vs 13.9 months, and median OS was 37.8 months vs 37.2 months, with no statistical significance. Safety profiles were consistent with expected toxicities.